GlaxoSmithKline Pharmaceuticals Limited

NSEI:GLAXO 株式レポート

時価総額:₹456.6b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

GlaxoSmithKline Pharmaceuticals マネジメント

マネジメント 基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Bhushan Akshikar

最高経営責任者

₹66.9m

報酬総額

CEO給与比率21.7%
CEO在任期間1.8yrs
CEOの所有権n/a
経営陣の平均在職期間2yrs
取締役会の平均在任期間6.4yrs

経営陣の近況

Recent updates

We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease

Aug 29
We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease

The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Aug 05
The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Investors Appear Satisfied With GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Prospects As Shares Rocket 26%

Jun 01
Investors Appear Satisfied With GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Prospects As Shares Rocket 26%

With EPS Growth And More, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Makes An Interesting Case

May 05
With EPS Growth And More, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Makes An Interesting Case

GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Popularity With Investors Is Clear

Apr 14
GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Popularity With Investors Is Clear

Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Feb 15
Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Is Now The Time To Put GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) On Your Watchlist?

Jan 18
Is Now The Time To Put GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) On Your Watchlist?

GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Investors Are Less Pessimistic Than Expected

Dec 28
GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Investors Are Less Pessimistic Than Expected

Here's Why We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Might Deserve Your Attention Today

Oct 05
Here's Why We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Might Deserve Your Attention Today

Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?

Sep 12
Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?

GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet

Mar 17
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet

Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?

Sep 02
Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?

GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly

Mar 02
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly

The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On

Mar 20
The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On

Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?

Feb 27
Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?

Declining Stock and Decent Financials: Is The Market Wrong About GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)?

Feb 06
Declining Stock and Decent Financials: Is The Market Wrong About GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)?

What Type Of Shareholders Make Up GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Share Registry?

Jan 11
What Type Of Shareholders Make Up GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Share Registry?

GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Shareholders Have Enjoyed A 26% Share Price Gain

Dec 06
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Shareholders Have Enjoyed A 26% Share Price Gain

Earnings Miss: GlaxoSmithKline Pharmaceuticals Limited Missed EPS By 48% And Analysts Are Revising Their Forecasts

Nov 01
Earnings Miss: GlaxoSmithKline Pharmaceuticals Limited Missed EPS By 48% And Analysts Are Revising Their Forecasts

Tread With Caution Around GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) 1.3% Dividend Yield

Oct 29
Tread With Caution Around GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) 1.3% Dividend Yield

What Kind Of Shareholders Hold The Majority In GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Shares?

Sep 29
What Kind Of Shareholders Hold The Majority In GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Shares?

If You Had Bought GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Stock A Year Ago, You Could Pocket A 30% Gain Today

Aug 30
If You Had Bought GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Stock A Year Ago, You Could Pocket A 30% Gain Today

Is GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Recent Performancer Underpinned By Weak Financials?

Aug 02
Is GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Recent Performancer Underpinned By Weak Financials?

It Might Not Be A Great Idea To Buy GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) For Its Next Dividend

Jul 12
It Might Not Be A Great Idea To Buy GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) For Its Next Dividend

Is GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) At Risk Of Cutting Its Dividend?

Jul 07
Is GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) At Risk Of Cutting Its Dividend?

CEO報酬分析

GlaxoSmithKline Pharmaceuticals の収益と比較して、Bhushan Akshikar の報酬はどのように変化したか?
日付総報酬給与会社業績
Jun 30 2024n/an/a

₹6b

Mar 31 2024₹67m₹15m

₹6b

Dec 31 2023n/an/a

₹5b

Sep 30 2023n/an/a

₹6b

Jun 30 2023n/an/a

₹6b

Mar 31 2023₹34m₹4m

₹6b

報酬と市場: Bhushanの 総報酬 ($USD 801.95K ) は、 Indian市場 ($USD 631.48K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Bhushanの報酬は過去 1 年間で 20% 以上増加しました。


CEO(最高経営責任者

Bhushan Akshikar

1.8yrs

在職期間

₹66,885,000

報酬

Mr. Bhushan Akshikar is Managing Director of GlaxoSmithKline Pharmaceuticals Limited from December 1, 2022. He served as Additional Director of GlaxoSmithKline Pharmaceuticals Limited since March 18, 2021...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Bhushan Akshikar
MD & Executive Director1.8yrs₹66.89mデータなし
Juby Chandy
Whole-Time Director & CFO2.4yrs₹68.92mデータなし
Chinmay Sharma
Executive Vice President of Human Resources3.8yrs₹37.40mデータなし
Aparajita Rajput
Vice President of Technologyless than a yearデータなしデータなし
Ajay Nadkarni
VP of Administration & Real Estate and Company Secretaryno data₹11.57mデータなし
Amit Pandey
Executive Vice President of Legal2.6yrsデータなしデータなし
Simrat Sohal
Vice President of Ethics & Compliance1.6yrsデータなしデータなし
Ransom D'Souza
Executive Vice President of Communications & Government Affairs7.4yrsデータなしデータなし
Sukanya Choudhary
Executive Vice-President of Regulatory Affairsno dataデータなしデータなし
Shourov Mukherjee
Executive Vice-President of Adult Vaccines2.2yrsデータなしデータなし
Upendra Singh
Executive Vice President of General Medicines1.8yrsデータなしデータなし
Sharmishta Mitra
Commercial Head - Paediatric Vaccines1.7yrsデータなしデータなし

2.0yrs

平均在職期間

経験豊富な経営陣: GLAXOの経営陣は 経験豊富 とはみなされません ( 1.8年の平均在職年数)。これは新しいチームを示唆しています。


取締役

名称ポジション在職期間報酬所有権
Bhushan Akshikar
MD & Executive Directorno data₹66.89mデータなし
Juby Chandy
Whole-Time Director & CFO2.4yrs₹68.92mデータなし
Renu Karnad
Non-Executive Chairperson5.4yrs₹3.25mデータなし
Manu Anand
Independent Director2.3yrs₹2.65mデータなし
Damodarannair Sundaram
Non-Executive Independent Director15.2yrs₹2.70mデータなし
Subesh Williams
Non Executive Director7.4yrsデータなしデータなし
Pradeep Bhide
Non-Executive Independent Director13.9yrs₹2.70mデータなし
Anami Narayan Roy
Non-Executive Independent Director12.8yrs₹2.45mデータなし
Sunita Maheshwari
Non-Executive & Independent Director4.3yrs₹2.45mデータなし

6.4yrs

平均在職期間

68.5yo

平均年齢

経験豊富なボード: GLAXOの 取締役会経験豊富 であると考えられます ( 6.2年の平均在任期間)。